Skip to content

Live Events
Sign Up / Login

Live Events
Sign Up / Login

MEC Basic Full List View

By pinki@katapult.biz / February 16, 2025

MEC Basic

Speciality

Author / Speaker

Title

Type of Media

Events

Search Everything

«
1
…
18
19
20
21
22
…
62
»

Most Relevant Data on Immunotherapy in Neo-Adjuvant, Adjuvant, and Metastatic NSCLC

Most Relevant Data on Immunotherapy in Neo-Adjuvant, Adjuvant, and Metastatic NSCLC

Luis E. Raez, MD, FACP, FCCP

Updates on Targeting ALK, ROS1 ,and RET in NSCLC

Updates on Targeting ALK, ROS1 ,and RET in NSCLC

Jessica Lin, MD

New Developments in EGFR and K-RAS Therapies in NSCLC

New Developments in EGFR and K-RAS Therapies in NSCLC

Edgardo S. Santos, MD, FACP

New Developments in Metastatic Breast Cancer: Immunotherapy and Novel Therapeutic Pathways

New Developments in Metastatic Breast Cancer: Immunotherapy and Novel Therapeutic Pathways

Joyce O’Shaughnessy, MD

Breast Cancer Update in Hormone Sensitive Breast Cancer

Breast Cancer Update in Hormone Sensitive Breast Cancer

Lauren Carcas, MD

Novel Frontiers in the Use of ctDNA in Oncology

Novel Frontiers in the Use of ctDNA in Oncology

Christian Rolfo, MD, PhD, MBA, Dr.hc.

Developments in Head and Neck Cancers Including Thyroid Malignancies

Developments in Head and Neck Cancers Including Thyroid Malignancies

Moises Harari-Turquie, MD

Gynecologic Malignancies: New Targeted Therapy-IO-Chemo Combinations

Gynecologic Malignancies: New Targeted Therapy-IO-Chemo Combinations

Ritu Salani, MD, MBA

Updates in Kidney and Bladder Cancers: Where we are with Immunotherapy and Precision Medicine?

Updates in Kidney and Bladder Cancers: Where we are with Immunotherapy and Precision Medicine?

Karine Tawagi, MD

Updates in Cholangiocarcinoma and Pancreas Cancer: What is new in Targeted Therapy or Immunotherapy?

Updates in Cholangiocarcinoma and Pancreas Cancer: What is new in Targeted Therapy or Immunotherapy?

Milind M. Javle, MD

Updates in Colorectal Cancer

Updates in Colorectal Cancer

Fernando de Zarraga, MD

Updates in Prostate Cancer: Combination Therapy Becoming the Best Approach?

Updates in Prostate Cancer: Combination Therapy Becoming the Best Approach?

Chandler Park, MD, FACP

Novel Therapies for Thymic Malignancies

Novel Therapies for Thymic Malignancies

Jonathan Riess, MD

Systemic Therapies for Mesothelioma

Systemic Therapies for Mesothelioma

Jorge E. Gomez, MD

Radiation Induced Immune-Response in NSCLC

Radiation Induced Immune-Response in NSCLC

Jeffrey Bradley, MD

Optimal Surgical Approach for Mesothelioma

Optimal Surgical Approach for Mesothelioma

Raja Flores, MD

What Comes After Immunotherapy Failure in Terms of More Immunomodulation (Anti-Angiogenic Agents, IL-15, OX-40 and Others)?

What Comes After Immunotherapy Failure in Terms of More Immunomodulation (Anti-Angiogenic Agents, IL-15, OX-40 and Others)?

Ticiana Leal, MD

Frontline: What are We Adding to Checkpoint Inhibitors and Chemotherapy?

Frontline: What are We Adding to Checkpoint Inhibitors and Chemotherapy?

Jyoti Patel, MD

Developing New Anti-CTL4s for NSCLC: Is There Any Role?

Developing New Anti-CTL4s for NSCLC: Is There Any Role?

Millie Das, MD

The Role of Co-Mutations with Immunotherapy Response in NSCLC

The Role of Co-Mutations with Immunotherapy Response in NSCLC

Ferdinando Skoulidis, MD

Role of Radiotherapy in TIME: Good? Bad? Don’t know?

Role of Radiotherapy in TIME: Good? Bad? Don’t know?

Puneeth Iyengar, MD

Overcoming T-Cell Exhaustion

Overcoming T-Cell Exhaustion

Brian S. Henick, MD

The New Role of Microbiome in Lung Cancer Immunotherapy

The New Role of Microbiome in Lung Cancer Immunotherapy

David Carbone, MD

Role of Interleukins in TIME to Improve Immunotherapy Efficacy

Role of Interleukins in TIME to Improve Immunotherapy Efficacy

Suresh Ramalingam, MD

The Importance of TIME in Cancer Fight: How to Target It?

The Importance of TIME in Cancer Fight: How to Target It?

Hossein Borghaei, DO

CAR-T Cell in NSCLC: Is it Feasible?

CAR-T Cell in NSCLC: Is it Feasible?

Sally Lau, MD

Updates in Bispecific Antibodies in NSCLC

Updates in Bispecific Antibodies in NSCLC

Lyudmila Bazhenova, MD

Targeting CEACAM5 and ROR1/ROR2 in NSCLC

Targeting CEACAM5 and ROR1/ROR2 in NSCLC

Paul Bunn, MD

TROP-2 and AXL as Targets in NSCLC

TROP-2 and AXL as Targets in NSCLC

Stephen Liu, MD

Building the Case for HER-2 Inhibitors in NSCLC

Building the Case for HER-2 Inhibitors in NSCLC

Corey Langer, MD

Displaying 571 - 600 of 1,833

Post navigation

← Previous View

6619 South Dixie Highway #341
Miami, FL 33143

Phone: 305.663.1628
Email: info@meccinc.com

Useful Links

Library
Live Events

Categories

MEC Basic
MEC Plus
Purchased

About Us

Why Subscribe
About Us
Accreditation

© 2025 MEC Inc. All rights reserved | Digital Marketing by Katapult Marketing

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok